Molecules 2008, 13(5), 1156-1178; doi:10.3390/molecules13051156
Review

Prodrugs in Cardiovascular Therapy

1,3, 4,5 and 1,2,3,* email
Received: 5 February 2008; in revised form: 14 May 2008 / Accepted: 14 May 2008 / Published: 14 May 2008
(This article belongs to the collection Prodrugs)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Prodrugs are biologically inactive derivatives of an active drug intended to solve certain problems of the parent drug such as toxicity, instability, minimal solubility and non-targeting capabilities. The majority of drugs for cardiovascular diseases undergo firstpass metabolism, resulting in drug inactivation and generation of toxic metabolites, which makes them appealing targets for prodrug design. Since prodrugs undergo a chemical reaction to form the parent drug once inside the body, this makes them very effective in controlling the release of a variety of compounds to the targeted site. This review will provide the reader with an insight on the latest developments of prodrugs that are available for treating a variety of cardiovascular diseases. In addition, we will focus on several drug delivery methodologies that have merged with the prodrug approach to provide enhanced target specificity and controlled drug release with minimal side effects.
Keywords: Prodrug; cardiovascular disease; drug-eluting stents; antiplatelet; antithrombin.
PDF Full-text Download PDF Full-Text [423 KB, uploaded 18 June 2014 19:28 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Sandros, M.G.; Sarraf, C.B.; Tabrizian, M. Prodrugs in Cardiovascular Therapy. Molecules 2008, 13, 1156-1178.

AMA Style

Sandros MG, Sarraf CB, Tabrizian M. Prodrugs in Cardiovascular Therapy. Molecules. 2008; 13(5):1156-1178.

Chicago/Turabian Style

Sandros, Marinella G.; Sarraf, Chady B.; Tabrizian, Maryam. 2008. "Prodrugs in Cardiovascular Therapy." Molecules 13, no. 5: 1156-1178.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert